Four months later, no improvement of stenoses was found in ultrasound and MRA studies. almost resolved completely in the other two patients. Side effects of MPTP hydrochloride corticosteroid treatment occurred in two patients. Conclusions Long-term combination treatment with prednisone and valacyclovir proved to be effective in three young men suffering from intracranial stenosis due to VZV vasculitis. strong class=”kwd-title” Keywords: Valacyclovir, Prednisone, VZV vasculitis, Intracranial stenoses Background Vasculitis associated with varicella zoster virus (VZV) is a rare cause of stroke. It can, however, be assumed that the condition is often not recognized and misdiagnosed [9]. VZV vasculopathy is a common synonym for VZV vasculitis, because in 33% of patients markers of inflammation are absent in cerebrospinal fluid (CSF) studies [22]. VZV was first described as a cause of stroke in 1896 [24] and has been associated with stroke caused by abnormalities in small and large intracranial arteries, aneurysms with or without subarachnoid hemorrhage, dolichoectasia, dissections, and cerebral venous thrombosis. A differentiation is made between VZV vasculitis of small cerebral arteries, in 37% of cases, and large cerebral arteries, reported to be affected in 13% of MPTP hydrochloride patients, respectively. Both large and small cerebral arteries were involved in 50% of patients [22]. An intrathecal synthesis of anti-VZV antibodies in combination with the detection of VZV deoxyribonucleic acid (DNA) in the CSF were described in 30% of the patients only, while anti-VZV IgG antibodies in the CSF alone were found in 93%. While positive polymerase chain reaction (PCR) and the detection of anti-VZV antibodies in the CSF are both highly specific, the detection of anti-VZV Ig antibodies in the CSF is the most reliable test to diagnose VZV vasculitis/vasculopathy. Strokes MPTP hydrochloride and lesions at the gray-white matter boundary are the hallmark of small-vessel VZV vasculopathy, while stenoses, especially of the M1 segment of the middle cerebral artery (MCA) or the terminal portion of the internal carotid artery (ICA) are characteristic for large-vessel VZV vasculopathy. These findings can be detected in contrast-enhanced high-resolution MRI [4]. Diagnosis of VZV vasculitis can be challenging because CSF pleocytosis is only found in 67% of patients and the interval between the manifestation of the typical VZV rash and stroke can be long [21]. Demographic data, showing an increased risk of stroke after chickenpox in adults and after shingles point to the significance of VZV in the etiology of stroke [15, 17]. Studies also showed an increased risk of stroke, especially after ophthalmic zoster, within the first 5C12?weeks after the acute infection [17]. VZV vasculopathy does not only occur in Human immunodeficiency virus (HIV)-positive pediatric and adult patients, but also in immunocompetent patients. MPTP hydrochloride Whether these supposedly immunocompetent patients have a genetic predisposition for VZV vasculopathies should be discussed in the light of the recently reported association between VZV central nervous system (CNS) vasculitis and deficiency in the cytosolic DNA sensor Ribonucleic acid (RNA) Polymerase III [3]. Pathophysiologically, reactivation of latent VZV in cranial nerve ganglia is assumed with VZV spreading along neuronal axons to infect the outermost layer of the arterial wall adventitia. Other findings include thickened intima with thickened myofibroblasts, disrupted internal elastic lamina, and thickened smooth muscle cells [26]. While early VZV vasculitis is associated with the presence of abundant neutrophils MPTP hydrochloride in the adventitia, the inflammatory response is reduced over the course of the disease by vascular remodeling, paralleling the changes observed in other cardiovascular and KRT13 antibody pulmonary vascular diseases [20]. In VZV vasculopathies, it was shown that VZV infection results in significantly increased levels of interleukin 8 in human vascular adventitial fibroblasts, in human perineurial cells, in.